Text Size
  • Home
    • About Dementia
    • What will early diagnosis of dementia look like by 2020?
    • The clinical / healthcare market
    • How will the impact of the project be measured?
    • What will be the impact of the project on the community?
    • Early and differential diagnosis
    • Clinical and Research Platforms
    • Technology solution
    • Research challenges
    • Multi-scale multi-factorial multiparadigm modelling
    • Track record of sharing
    • Research platforms
    • The industrial/commercial market
    • Technology Assessment, Market Analysis and Exploitation
    • Health technology assessment (HTA)
  • Project
    • Objectives
    • Benefits
    • Exploitation
    • Indicators
    • Work Packages
      • WP1
      • WP2
      • WP3
      • WP4
      • WP5
      • WP6
      • WP7
      • WP8
      • WP9
      • WP10
  • Research
    • People
    • Challenges
    • Platforms
    • Public Deliverables
    • Scientific Advisory Board
  • Partners
    • 1USFD.jpg USFD
    • 3VTT.jpg VTT
    • 4ESI.jpg ESI
    • 5ASD.jpg ASD
    • 6EMP.jpg EMP
    • 7UIO.jpg UIO
    • 8EMC.jpg EMC
    • 9HIRS.jpg HIRS
    • 10PMS.jpg PMS
    • 11ETHZ.jpg ETHZ
    • 12KCL.jpg KCL
    • 13PRH.jpg PRH
    • 14STH.jpg STH
    • 15UCL.jpg UCL
    • 16UEF.jpg UEF
    • 17UMA.jpg UMA
    • 18TO.jpg TO
    • 19ICL.jpg ICL
    • 20EIBIR.jpg EIBIR
    • sab.jpg SAB
  • Dissemination
    • Newsroom
    • Press Package
    • Press Releases
      • Videos
    • Newsletter
  • Publications
Dr. Paulien Aalten

Dr. Paulien Aalten

Dr Paulien Aalten, neuropsychologist, co-ordinates the national AD biomarker studies and will contribute to WP1.
Website URL: http://mhens.unimaas.nl/vervolgpagina/1055/4/Aalten/
Role: Researcher

Contact Details

  • Title
  • E-mail:
    p.aalten@maastrichtuniversity.nl
  • Address
    P.O. Box 616, 6200 MD Maastricht The Netherlands
  • City
    Maastricht
  • Country
    Netherlands
  • Telephone
    +31-43-3884104